Catalyst Biosciences, Inc. (CBIO): Price and Financial Metrics
CBIO Price/Volume Stats
| Current price | $7.67 | 52-week high | $8.69 |
| Prev. close | $0.53 | 52-week low | $0.19 |
| Day low | $7.20 | Volume | 32,246 |
| Day high | $8.69 | Avg. volume | 763,526 |
| 50-day MA | $0.50 | Dividend yield | N/A |
| 200-day MA | $0.33 | Market Cap | 291.27M |
CBIO Stock Price Chart Interactive Chart >
Catalyst Biosciences, Inc. (CBIO) Company Bio
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on engineering proteases as therapeutics for hemophilia, hemeostasis, complement-mediated diseases, and other unmet medical needs. The company is based in South San Francisco, California.
Latest CBIO News From Around the Web
Below are the latest news stories about CATALYST BIOSCIENCES INC that investors may wish to consider to help them evaluate CBIO as an investment opportunity.
Is Catalyst Biosciences (CBIO) Significantly Overvalued?An Analysis of the Intrinsic Value and Future Prospects |
Catalyst Biosciences, Inc. (NASDAQ:CBIO) insiders placed bullish bets worth US$941k in the last 12 monthsIn the last year, multiple insiders have substantially increased their holdings of Catalyst Biosciences, Inc... |
12 Cheap Healthcare Stocks to Buy in 2023In this piece, we will take a look at the twelve cheap healthcare stocks to buy in 2023. For more healthcare stocks, head on over to 5 Cheap Healthcare Stocks to Buy in 2023. The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades. Modern […] |
Catalyst Biosciences Provides Corporate UpdateSOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”) |
Catalyst Biosciences Completes First Steps in Reverse Merger PlanAcquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21 |
CBIO Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 2.27% |
| 1-year | 113.95% |
| 3-year | -88.76% |
| 5-year | -94.12% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -42.29% |
| 2021 | -85.52% |
| 2020 | -7.34% |
| 2019 | -13.69% |
Loading social stream, please wait...